Purpose: We designed this study to examine the clinical effects of polymyxin B hemoperfusion (PMX-HP) in septic shock patients. Material and methods: We retrospectively examined the effects of PMX-HP in septic shock patients with intra-abdominal or gram-negative bacterial infection during October 2013-May 2016. A one-to-one matching between the PMX-HP and conventional groups was performed, and 28-day mortality, and change in inotropic score, Sequential Organ Failure Assessment (SOFA) score, and Acute Physiology and Chronic Health Evaluation II (APACHE II) score at 24 h in the two groups were compared. In addition, multivariable regression analysis and Cox proportional hazards regression model were applied in all eligible patients. Results: Sixty-nine patients were eligible, of whom forty-eight patients were enrolled for matched cohort analysis. In matched cohort analysis, median change in inotropic score after 24 h (−23 [−33-−13] vs. −12 [−19-0], p = 0.007) differed significantly between the PMX-HP and conventional groups. Multivariable regression analysis revealed that PMX-HP was associated with lower 28-day mortality (odds ratio 0.18, 95% CI 0.04-0.92, p = 0.039) and greater improvement in inotropic and APACHE II scores. Conclusions: PMX-HP may have potential benefits for hemodynamic and prognostic outcomes in septic shock patients with intra-abdominal or gram-negative bacterial infection.
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Introduction
Endotoxin, a major component of gram-negative bacterial outer membrane, is a key factor in the pathogenesis of severe sepsis and septic shock, and endotoxin-targeted therapy has been developed in recent decades [1, 2] . Polymyxin B immobilized fiber cartridge is one of the devices that has been proven to effectively remove endotoxin [3] [4] [5] . Many clinical studies have access the potential benefit of polymyxin B hemoperfusion (PMX-HP) in septic shock patients with intra-abdominal infection or systemic gram-negative bacterial infection. The EUPHAS randomized controlled trial [6] and a meta-analysis [7] have both suggested that PMX-HP significantly improves hemodynamics and reduces the risk of organ dysfunction and 28-day mortality in patients with septic shock. However, a recent Japanese nationwide database retrospective study [8] reported no survival benefit of PMX-HP in abdominal septic shock patients. In another recent randomized controlled trial [9] , PMX-HP nonsignificantly increased the 28-day mortality by 8.2% in peritonitis-induced septic shock patients after surgery. These remarkable differences in the results is attributable to the differences in the studied populations, thus raising the question whether PMX-HP has clinical benefits only in well-defined septic shock patients [10] with appropriate disease severity and prompt initiation of PMX-HP treatment. Due to the discrepancy of results from different studies, we performed a retrospective study to examine the effects of PMX-HP in septic shock patients with intra-abdominal or gram-negative bacterial infection in a medical center of Taiwan.
Materials and methods
Study design and selection of patients
This is a retrospective cohort study of critically ill patients diagnosed with septic shock during October 2013-May 2016 in five surgical intensive care units (5 SICUs; 61 beds) of a medical center in Taiwan. This study was approved by the Research Ethic Committee of National Taiwan University Hospital (201605108RINB). Septic shock patients who met one of following inclusion criteria were selected: (1) with intra-abdominal infection, having received emergent abdominal surgery or drainage procedure and (2) with evidence for systemic gram-negative bacterial infection under adequate antibiotic treatment. Septic shock was defined according to the consensus definition of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee [11] . The exclusion criteria were: (1) those who were younger than 20 years or older than 90 years, (2) pregnant women, (3) those who had experienced uncontrolled hemorrhage within 24 h before ICU admission, (4) those who had undergone cardiopulmonary resuscitation within 24 h before ICU admission, (5) those who had undergone organ transplantation within 1 year, (6) those diagnosed with immunodeficiency disorder, and (7) terminally ill patients with a do-not-resuscitate order. All septic shock patients received sepsis management according to the Surviving Sepsis Campaign guidelines in our hospital [12] . Patients who received PMX-HP treatment were allocated to the PMX-HP group, and the others were allocated to the conventional group. Hemoperfusion was performed for 2 h in the ICU by using an extracorporeal hemoperfusion cartridge with polymyxin B immobilized on polystyrene fibers (Toraymyxin, Toray Industries Inc., Tokyo, Japan). Unfractionated heparin was used as the anticoagulant according to the manufacturer instructions, and the dose of heparin was adjusted according to patients' clinical condition by intensivists. When required, the subsequent session of PMH was performed 24 h after the end of the prior session.
Data collection and outcomes
Patient characteristics, clinical data, and prognoses were collected through complete medical chart review. Inotropic score, Sequential Organ Failure Assessment (SOFA) score [13] , and Acute Physiology and Chronic Health Evaluation II (APACHE II) score [14] were obtained at baseline and 24 h after. For patients admitted for septic shock, the baseline was defined as the ICU admission when the requirement of norepinephrine was N0.1 mcg/kg/min or when the requirement of norepinephrine increased to N0.1 mcg/kg/min. For patients not admitted for septic shock, the baseline was defined as the time when the norepinephrine requirement increased to N0.1 mcg/kg/min after septic shock onset. Inotropic score was calculated as 100 × epinephrine dose (mcg/kg/min) + 100 × norepinephrine dose (mcg/kg/min) + dopamine dose (mcg/kg/min) + dobutamine dose (mcg/kg/min) [15] . For this study, we defined hemodynamic outcome as the change in inotropic score after 24 h and prognostic outcomes as 28-day mortality, and the change in SOFA score or APACHE II score after 24 h.
Matched cohort analysis and regression analysis
A one-to-one matching between the conventional group and the PMX-HP group was performed on the basis of demographic data including age, gender, and baseline SOFA score. As matching excluded patients who were not selected in the process, we conducted regression analysis for all eligible patients. Variables such as age, gender, baseline SOFA score, baseline inotropic score, PMX-HP, and continuous renal replacement therapy (CRRT) in 24 h were used to identify the predictors of hemodynamic and prognostic outcomes. Before regression analysis, we calculated the variance inflation factor (VIF) for these variables. To avoid the multicollinearity, variables with a VIF ≥ 5 were excluded. Moreover, the Cox proportional hazards regression model was applied to plot the adjusted 28-day survival curve. We used time-by-covariate interactions for PMX-HP to check the proportional hazard assumption.
Statistical analysis
All analyses in the present study were performed using the SPSS Statistics software package V.20 (IBM, Chicago, USA). Categorical variables are presented as proportions and were tested using χ2 test or Fisher exact test. Continuous variables are presented as median (interquartile range) and were tested using the Mann Whitney U test. Linear regression was used for the continuous variables, and the results are presented as coefficient with 95% confidence interval (CI); logistic regression was used for the categorical variables, and the results are presented as odds ratio (OR) with 95% CI; the Cox proportional hazards regression model was used for the survival analysis, and the results are presented as hazard ratio (HR) with 95% CI. Patients were censored if they were alive at the end of follow-up. The level of statistical significance is set at 5% throughout this study.
Results
Of the 167 patients assessed for the eligibility, 27 patients in the PMX-HP group and 42 patients in the conventional group were enrolled for final analysis (Fig. 1) . Twenty-four pairs of patients were obtained for matched cohort analysis. Characteristics of matched and unmatched patients in the PMX-HP and conventional groups are summarized in Table 1 . The median initiation of PMX-HP treatment was 14 (9-18) h for patients undergoing surgical interventions. In the unmatched cohort, we observed higher baseline disease severity (SOFA score or APACHE II score), baseline inotropic score, and CRRT rate in the PMX-HP group than those in the conventional group. The 28-day mortality was 22 % for the PMX-HP group and 31 % for the conventional group (p = 0.582). The median change in inotropic score after 24 h was -22 (-33 --11) for the PMX-HP group and -9 (-15-0) for the conventional group (p = 0.001). The median change in SOFA score after 24 h was -1 (-3-1) for the PMX-HP group and 0 (-3-1) for the conventional group (p = 0.424). The median change in APACHE II score after 24 h was -4 (-7--1) for the PMX-HP group and -2 (-4-0) for the conventional group (p = 0.021). Table 2 summarizes the results from the matched cohort analyses. Patients in the PMX-HP group had nonsignificant lower 28-day mortality (17% vs. 46%, p = 0.06) and significantly higher reduction in the inotropic score, SOFA score, and APACHE II score after 24 h than did those in the conventional group.
The VIF for the variables such as age, gender, baseline SOFA score, baseline inotropic score, PMX-HP, and CRRT in 24 h were all b5, and these variables were used in all regression models applied in the present study. Table 3 shows the results from multivariable logistic regression analysis for 28-day mortality. We observed that PMX-HP was an independent predictor of lower 28-day mortality (OR 0.18, 95% CI 0.04-0.92, p = 0.039). Table 4 shows the results from multivariable linear regression analyses for change in inotropic score, SOFA score, and APACHE II score after 24 h. The PMX-HP was correlated with a higher reduction in the inotropic score (p = 0.003) and SOFA score (p = 0.023) after 24 h. In the Cox proportional hazards regression model, the time-by-covariate interactions for PMX-HP was not statistically significant (p = 0.487), and therefore we concluded that the proportional hazard assumption was met. Fig. 2 presents the results from the Cox proportional hazards regression model for adjusted survival s8-days curve; the HR for death in the PMX-HP group was 0.29 (95% CI 0.09-0.92, p = 0.035).
Discussion
Our results suggest that PMX-HP improves hemodynamic and prognostic outcomes in septic shock patients with intra-abdominal or gram-negative bacterial infection. More reduction of vasopressor requirement and disease severity score and lower 28-days mortality were observed after PMX-HP treatment, as supported by the results from matched cohort analyses and multivariable regression analyses.
The survival benefit of PMX-HP in our study corresponded with previous randomized trials (OR 0.11-0.42) [6, [16] [17] [18] [19] . In septic shock patients, removal of endotoxin by PMX-HP inhibits the activation of proinflammatory cells and reduces plasma cytokines level [20] . These effects may contribute to two major clinical benefits as follows: First, PMX-HP improves hemodynamic stability. Although the pathophysiology of cardiac dysfunction in septic shock is complicated, cytokines have been implicated in many studies [21, 22] . Many studies have confirmed that PMX-HP effectively improves hemodynamic status by increasing mean arterial pressure and cardiac index, and by decreasing vasopressor requirement [6, 19, 23, 24] . In this study, PMX-HP was also observed to correlate with lower vasopressor requirement. Second, PMX-HP protects vital organs. The immunoinflammatory response induced by uncontrolled cytokines in septic shock patients causes multiple organ dysfunction syndrome, which is recognized as the major factor contributing to death in septic shock patients [25, 26] . A meta-analysis and two randomized trials reported that PMX-HP improved pulmonary oxygenation and SOFA score [6, 7, 23] . In this study, PMX-HP was also observed to correlated with much improved SOFA and APACHE II scores. Moreover, two more potential benefits of PMX-HP have been proven in animal studies: First, PMX-HP may improve microcirculation. Microcirculation has been identified as a key factor in sepsis in recent era, while cytokines has been hypothesized to adversely affect microcirculation [27] . Iba et al. pointed out that microcirculation was more effectively maintained with the use of PMX-HP on the basis of series of rats models [28, 29] , and the efficacy of PMX-HP in improving microcirculation was also described in a preliminary report of a clinical randomized controlled trial [30] . Second, PMX-HP may interrupt the vicious cycle of dysregulated innate immunity. Neutrophil recruitment to the infection site is a core part of innate immunity. Abnormal accumulation of bacterial products, cytokines, and other immunomodulatory hormones in septic shock may dysregulate neutrophil chemotaxis, thus further making them defective in innate immunity [31, 32] . In a recent rat model study, removal of plasma cytokine and chemokine redirected leukocyte trafficking and reduced leukocyte infiltration into the lung [33] . However, future clinical trials are warranted to investigate these effects in septic shock patients.
The diversity of patients' disease severity among studies may partially explain the remarkable differences among the results of studies examining the survival benefit of PMX-HP. The 28-day mortality of the control group was 48% in our study, 53.3% in the EUPHAS trial [6] , and 46.8% in a recent large retrospective study [34] , and survival benefit of PMX-HP was shown in these studies. By contrast, a recent randomized controlled trial by Payen et al. [9] recommended against the use of PMX-HP to treat peritonitis-induced septic shock after surgery. However, the 28-day mortality of the control group was 19.2% in their study. Additionally, the randomized controlled trial by Nemoto et al. suggested no survival benefit of PMX-HP in the advanced stage of septic shock (i.e., in septic shock patients with APACHE II score N 30). We are not the first to propose that PMX-HP may only have clinical benefits in well-defined septic shock patients [10] with appropriate disease severity and prompt initiation of PMX-HP treatment. In septic patients with mild disease severity, timely resuscitation would assist the innate immunity to overcome sepsis. In septic patients with moderate-tosevere disease severities, early removal of endotoxin may assist in confining organ damage by preventing further cytokine cascade. In septic patients with extremely severe disease severity, removal of endotoxin may not result in clinical benefits after the development of irreversible multiple organ dysfunction. However, additional clinical trials are necessary to clarify the effect of PMX-HP in septic shock patients with different disease severities.
Our study was limited by two major factors. First, it was a retrospective study with limited number of patients. Second, although we used matching method and regression model to adjust the effect of suspected confounder, potential bias from unmeasured confounder exists in this study. Because PMX-HP was not covered by National Healthcare Insurance in Taiwan, patients' socio-economic status was a confounder. 
Conclusion
In conclusion, our results suggest that PMX-HP has benefits on hemodynamic and prognostic outcomes in septic shock patients with intra-abdominal or gram-negative bacterial infection. Additional trials are warranted to determine the clinical benefits and cost-effectiveness of PMX-HP in septic shock patients with different disease severities.
